Article

PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its LDL cholesterol-lowering effects

2024-08-28

Abstract excerpt

<h4>BACKGROUND</h4> Circulating levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), which regulates plasma cholesterol content by degrading LDL receptor, are correlated with the risk of acute myocardial infarction (AMI). Recent studies suggested that PCSK9 improves cardiac function beyond its effects on LDL cholesterol levels after cardiac ischemic injury, but its precise mechanism remains unclear. <h...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bdd022dc-479c-52c8-8779-53f1bbf04f11
DOI: 10.1101/2024.08.27.24312680

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PCSK9 inhibition in myeloid cells enhances cardioprotection beyond its LDL cholesterol-lowering effectsDOI 10.1101/2024.08.27.24312680Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagySemantic proximity Read

The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulationSemantic proximity Read

Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall.Semantic proximity Read

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerSemantic proximity Read

The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Semantic proximity Read

miR487a-3p and miR6855-3p Facilitate Macrophage Pro-inflammatory Polarization and Lipid Accumulation in AtherosclerosisSemantic proximity Read

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read

Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular diseaseSemantic proximity Read

New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.Semantic proximity Read

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read